第二届World ADC亚洲高峰会议

Antibody-drug conjugate development has seen real progression over the last year within Asia. From our research with Miracogen, Remegen and MedImmune we can expect to see real advances in 2019. Now in its second year, World ADC Asia (June 11-13, Shanghai, China) is back following its initial success to overcome the challenges ADC drug developers are facing.
去年，亚洲抗体-药物偶联剂（Antibody-drug conjugates，缩写为“ADC”）的开发已经取得了确实的进步。从我们与上海美雅珂生物技术有限公司 (Miracogen)、荣昌生物制药（烟台）有限公司 (Remegen) 以及大型生物制剂研发公司MedImmune共同进行的研究来看，我们可以预期在2019年看到切实的进展。去年首届“World ADC 亚洲高峰会议”(World ADC Asia) 大获成功，今年它再度回归，第二届盛会（6月11-13日在中国上海举行）旨在克服ADC药物开发人员面临的各种挑战。

Across 3 days, with 120+ ADC experts, this comprehensive antibody-drug conjugates conference will enable you to propel your ADC pipeline into clinical development. You’ll explore lessons learned from working with regulatory bodies, reviewing latest phase I clinical readouts and confidently optimize ADC CMC processes to improve your manufacturing programs. Not only will World ADC Asia delve into general antibody-drug conjugate challenges is will also focus on challenges and opportunities specific to development within Asia.
此次综合性抗体药物偶联物会议为期3天，由120多位ADC专家组成。届时，您将有机会推动ADC管线进入临床开发。此次会议将回顾最新一期临床数据，与您一道探讨总结与监管机构合作的经验教训，并致力于优化ADC CMC流程，从而改进您的制造计划。World ADC Asia不仅将深入研究一般抗体药物偶联物面临的挑战，还将重点关注针对亚洲区域内发展的挑战和机遇。

Attend World ADC Asia to network with potential collaborators, foster new connections and further cement existing partnerships. This is the only ADC focused conference that will bring together all the key players within antibody-drug conjugates in Asia.
参与World ADC Asia 会议，与潜在合作伙伴建立联系，不仅意味着与新伙伴建立联系并且将进一步巩固现有合作关系。World ADC Asia 会议是唯一一个聚焦ADC的会议，将汇集亚洲范围内所有活跃在抗体药物偶联物领域的重要人物。

Join expert speakers from large pharma, biotech companies, research institutions, regulatory bodies and technology experts who are accelerating the discovery and treatment of antibody-drug conjugates.
参会人员包括：来自大型制药公司、生物技术公司、研究机构、监管机构的专家发言者，以及正积极发现和治疗抗体药物偶联物的技术专家。

Attendees" seniority & geographic
专业观众及来源国家：